Therapy Area topics
Cardiovascular
Medtronic bows to the inevitable
Paying $1.1bn for Heartware five years ago was not the company’s smartest move.
Medtronic’s Hugo still a long way from victor
The world’s biggest medtech expects great things from its new surgical robot, but its best shot at leading a market with a new product remains renal denervation.
The future of renal denervation
The pivotal trial of Medtronic’s hypertension device came out more than a year ago, yet the company has still not sought approval.
Central Nervous System
Biogen deals the tau pipeline another blow
The failure of gosuranemab could bode ill for Abbvie’s ABBV-8E12 in particular.
Sage depressed by Waterfall
The data were statistically significant, but the market had been hoping for more.
The next wave of amyloid-targeting projects approaches
Acumen is the latest player to take aim at amyloid, but competition is fierce.
Diabetes
Go or no go? Aducanumab’s day of reckoning
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Lilly leads the big pharma pack on pipeline value
Huge hopes for diabetes and Alzheimer’s projects swell Lilly’s pipeline valuation, with Glaxosmithkline and Abbvie looking bare in comparison.
Digital Health
Google gears up to launch its first medical device
But with Derm Assist available free, how will the company make money?
Oncology
EQRX vows to slash drug prices where others have failed
Promises to act on pharma’s financial toxicity increasingly seem to lack bite, but EQRX promises to follow its words with real action.
Guardant steps into a new arena
A test that tracks response to therapy is useful, but approval and reimbursement will be key.
Respiratory
Vertex’s second try at a rare lung disorder
A small molecule for alpha-1 antitrypsin deficiency faces a key clinical test, and its chances of success aren’t good.
Various
Go or no go? Aducanumab’s day of reckoning
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
